Comparing [177Lu]Lu-DOTATATE with standard treatment for recurrent intracranial meningioma

MOMENTUM-1: A Multicenter, Randomized, Open-Label, Phase II Study of [177LU]LU-DOTATATE in Adults With Progressive Intracranial Grade 1-3 Meningioma

This trial will test whether the radiopharmaceutical [177Lu]Lu-DOTATATE can help adults with recurrent or progressive grade 1–3 intracranial meningioma compared with standard treatments.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 153 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: RTOG Foundation, Inc. (Academic / other)
• Drugs / interventions: chemotherapy, radiation
• Locations: 11 sites (La Jolla, California and 10 other locations)
• Trial ID: NCT06955169 on ClinicalTrials.gov

What this trial studies

This is an open-label, multicenter, randomized phase 2 trial that assigns participants in a 2:1 ratio to receive either [177Lu]Lu-DOTATATE or standard-of-care therapy chosen by the local investigator. Eligible patients are adults with histologically confirmed WHO grade 1–3 meningioma and measurable progressive disease by RANO criteria. Participants on the standard-of-care arm may cross over to receive [177Lu]Lu-DOTATATE at the time of progression, and central radiology review will be used to confirm outcomes. Clinical and radiographic follow-up will be used to measure treatment activity and safety.

Who should consider this trial

Good fit: Adults (≥18) with histologically confirmed WHO grade 1–3 intracranial meningioma that has progressed after prior treatment and who have at least one measurable lesion per RANO criteria are the intended candidates.

Not a fit: Patients without measurable or progressive disease, those with major comorbidities or poor performance status, or those unable to attend a participating site are unlikely to benefit from this trial.

Why it matters

Potential benefit: If successful, this treatment could shrink or slow growth of recurrent meningiomas and provide a new targeted option for patients who have progressed after prior therapies.

How similar studies have performed: Lutetium-177 DOTATATE is an established therapy for somatostatin-receptor–positive neuroendocrine tumors and small observational and early-phase reports have suggested activity in meningioma, but randomized evidence in meningioma remains limited.

Eligibility criteria

Inclusion Criteria:

STEP 1 REGISTRATION

* Aged \>= 18 years
* Histologically confirmed diagnosis of WHO grade 1-3 meningioma
* Presence of measurable contrast-enhancing disease on gadolinium-enhanced MRI brain scan defined as at least one lesion with two perpendicular diameters measuring ≥10 mm on two or more axial slices (≤ 5 mm interslice thickness, ≤ 1 mm interslice gap) per current RANO meningioma criteria
* Progression of disease determined by local radiology review per current RANO meningioma criteria, defined as

  * ≥ 15% increase in sum of product of perpendicular measurements of up to 5 measurable target lesions within the last 6 months, or
  * ≥ 25% increase in sum of product of perpendicular measurements of up to 5 measurable target lesions within the last 12 months, or
  * Development of a new measurable lesion
* The following scans must be available for submission for central radiology review:

  * Pre-progression gadolinium-enhanced MRI brain scan
  * Progression gadolinium-enhanced MRI brain scan

STEP 2 REGISTRATION

* Progression of disease determined by central radiology review per current RANO meningioma criteria, defined as

  * ≥ 15% increase in sum of product of perpendicular measurements of up to 5 measurable target lesions within the last 6 months, or
  * ≥ 25% increase in sum of product of perpendicular measurements of up to 5 measurable target lesions within the last 12 months, or
  * Development of a new measurable lesion.
* \[68Ga\]Ga-DOTATATE uptake on PET-CT. Positive uptake is defined as uptake at least as high as liver, based on the uptake in at least one target lesion.
* If randomized to the control (standard of care) arm, both the patient and investigator must agree NOT to receive SSTR2-targeted therapy, surgical resection, or radiation therapy.
* Patients must be willing and able to undergo regular MRI scans of the brain and \[68Ga\]Ga-DOTATATE PET-CT imaging during the study.
* Patients must have recovered to CTCAE grade ≤1 or pretreatment baseline from clinically significant adverse events related to prior therapy (exclusions include alopecia, lymphopenia, sensory neuropathy ≤ grade 2, or other ≤ grade 2 not constituting a safety risk based on the investigator's judgment).
* Adequate organ and bone marrow function as defined below (within 28 days prior to step 2 registration):

  * Absolute neutrophil count (ANC) ≥ 1500/mm3
  * Platelet count ≥ 75,000/mm3
  * Hemoglobin ≥ 8 g/dL
  * Creatinine clearance (calculated by the Cockroft-Gault method) ≥40mL/min
  * Total serum bilirubin ≤ 3 x ULN (except participants with Gilbert's Syndrome, who can have a total bilirubin ≤ 5 x ULN)
  * Potassium within normal limits.

Exclusion Criteria:

* Patients with a clinical diagnosis of NF2-related schwannomatosis or with a known molecular diagnosis of NF2-related schwannomatosis.
* Patients with radiation-associated meningiomas.
* Patients with known intraspinal meningiomas or meningioma metastases outside the skull/spinal column.
* Prior SSTR2-targeted therapy, e.g. Somatostatin LAR or short-acting Octreotide.
* Unstable neurological symptoms requiring steroids to control symptoms at a dose of \>2 mg of dexamethasone (or equivalent) daily within 28 days prior to step 2 registration.
* Patients requiring immediate local therapy (e.g. surgical resection).
* Surgical procedure within the timeframes listed below, prior to step 2 registration.

  * 28 days from any prior craniotomy
  * 7 days from stereotactic biopsy Note: There is no limit to the number of prior surgical interventions
* Treatment within the timeframes specified below, prior to step 2 registration.

  * 28 days (or 5 half-lives, whichever is longer) for cytotoxic chemotherapy, biologic agent, investigational agent or any other systemic agent prescribed for the purpose of treating meningioma
  * 6 weeks from nitrosoureas Note: There is no limit to the number of prior systemically administered therapeutic agents.
* Prior external beam radiation, interstitial brachytherapy or stereotactic radiosurgery cumulative radiation dose of \> 70 Gy or the last dose of radiotherapy \< 24 weeks (6 months) prior to step 2 registration
* Peptide receptor radionuclide therapy at any time prior to registration.
* Known hypersensitivity to somatostatin analogues or any component of the \[68Ga\]Ga- DOTATATE or \[177Lu\]Lu-DOTATATE formulations.
* Active infection requiring current use of intravenous therapy with antibiotics.
* Active cardiovascular disease: cerebral vascular accident/stroke (≤ 6 months prior to registration), myocardial infarction (≤ 6 months prior to registration), congestive heart failure (≥ NYHA class II), unstable angina pectoris, or serious cardiac arrhythmia requiring medication.
* An active malignancy ≤ 3 years. Note: Patients with a malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
* Pregnant and/or breastfeeding patients who are unwilling to discontinue breast feeding.
* Participants of childbearing potential must have a negative pregnancy test within 14 days of study entry.

Where this trial is running

La Jolla, California and 10 other locations

• University of California San Diego - Moores Cancer Center — La Jolla, California, United States (Recruiting)
• Yale University — New Haven, Connecticut, United States (Recruiting)
• Baptist MD Anderson Cancer Center — Jacksonville, Florida, United States (Recruiting)
• University of Miami — Miami, Florida, United States (Recruiting)
• Baptist Health Medical Group Oncology — Miami, Florida, United States (Recruiting)
• Piedmont Healthcare — Atlanta, Georgia, United States (Recruiting)
• Indiana University — Indianapolis, Indiana, United States (Recruiting)
• Dana-Farber/Harvard Cancer Center — Boston, Massachusetts, United States (Recruiting)
• University of Michigan Rogel Cancer Center — Ann Arbor, Michigan, United States (Recruiting)
• Duke University Medical Center — Durham, North Carolina, United States (Recruiting)
• Medical College of Wisconsin — Milwaukee, Wisconsin, United States (Recruiting)

Study contacts

• Principal investigator: Erik P Sulman, MD,PhD — Duke University
• Study coordinator: Sylvia C Kurz, MD,PhD

Conditions Intracranial Meningioma; MOMENTUM-1; Meningioma; Advanced Intracranial Meningioma; SSTR2; Radiopharmaceuticals; Theranostics; Radioligand Therapy